Carregant...

Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy

Immune checkpoint inhibitor (ICI) therapies can achieve meaningful tumor responses in a subset of patients with most types of cancer that have been investigated. However, the majority of patients treated with these drugs do not experience any clinical benefit. Because not all patients benefit from I...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hum Vaccin Immunother
Autors principals: Lee, Mark, Samstein, Robert M., Valero, Cristina, Chan, Timothy A., Morris, Luc G.T.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7012182/
https://ncbi.nlm.nih.gov/pubmed/31361563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1631136
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!